Indivior Prepays Debt

Slough, UK and Richmond, VA, November 30, 2018 – Indivior PLC (LON: INDV) today announced that it has completed the prepayment of $85 million of principal of its outstanding Term loan facilities. This amount is in addition to the $150 million of outstanding Term loan principal the Company prepaid last September. As a result, outstanding borrowing under the Term loan facilities is now $244 million.

For Further Information

Investor Enquiries
Jason Thompson
VP Investor Relations, Indivior PLC
+1 804 379 1033
jason.thompson@indivior.com
 

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. The name is the fusion of the words individual and endeavour, and the tagline “Focus on you” makes the Company’s commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more.